Symbols

ALLK(Delisted)

Allakos·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ALLK

Allakos Inc.

A clinical stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases

Industry

Established Date

Listing Date

07/19/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.allakos.com

Security Type

Common stock

Office address

149 Commonwealth Dr Suite 1090, Menlo Park, California 94025

Business

Introduction

Allakos Inc., was incorporated in Delaware in March 2012. The company is a clinical-stage biotechnology company that develops therapies for immunomodulatory receptors present on immune effector cells associated with allergies, inflammation and proliferative diseases. AK006 targets Siglec-6, an inhibitory receptor selectively expressed on mast cells, a widely distributed white blood cell in the body that plays a central role in the inflammatory response.

Company Financials

EPS

ALLK has released its 2024 Q4 earnings. EPS was reported at 0, versus the expected -0.18, beating expectations. The chart below visualizes how ALLK has performed over recent quarters, highlighting trends in earnings surprises.